ACET Should I Buy

ACET is not a good buy right now for a Beginner long-term investor with $50k–$100k who wants to act immediately. The stock is a high-volatility, pre-revenue biotech coming off a reverse split, with no near-term news catalysts and worsening losses YoY. While technicals are mildly constructive and analysts remain broadly bullish (targets adjusted for the split), the options market shows extremely one-sided call positioning and extremely high implied volatility—more consistent with speculative trading than a stable long-term entry. If you want a long-term core position today, this is not the right fit; it’s more suitable only as a small, speculative biotech bet.

Price/levels: Pre-market 8.67, trading above the pivot (8.335) and approaching first resistance (R1 8.824). A clean break above 8.824 could open room toward R2 9.126; failure near resistance raises risk of a pullback toward S1 7.846. Momentum: MACD histogram is positive (0.115) but contracting, implying bullish momentum is present but weakening. RSI: RSI(6) ~59, neutral-to-slightly-bullish (not overbought). Trend/structure: Converging moving averages suggest a transition phase (no strong established trend). Pattern-based short-term odds: Similar-pattern projection is slightly negative over 1 week (-1.62%) and near-flat over 1 month (+0.28%), which does not support an urgent long-term entry. Intellectia Proprietary Trading Signals: **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.